Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aldoxo
2. Doxo-emch
3. Inno-206
1. Inno-206
2. 1361644-26-9
3. Doxorubicin-emch
4. Doxo-emch
5. Aldoxorubicin [usan]
6. N-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
7. Aldoxorubicin (usan)
8. 151038-96-9
9. C28mv4im0b
10. Aldoxorubicin [inn]
11. Aldoxorubicin [who-dd]
12. Chembl2107818
13. Schembl15221892
14. Dtxsid001098062
15. Ex-a3971
16. Aldoxorubicin;inno 206;inno206
17. Nsc784722
18. Zinc163337436
19. Cs-1186
20. Db06013
21. Nsc-784722
22. Hy-16261
23. D10383
24. (6-maleimidocaproyl)hydrazone Of Doxorubicin
25. (8s)-1-methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
26. 1h-pyrrole-1-hexanoic Acid, 2,5-dihydro-2,5-dioxo-, (1-((2s,4s)-4-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide
27. 1h-pyrrole-1-hexanoic Acid, 2,5-dihydro-2,5-dioxo-, (1-(4-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2s-cis)-
28. 1h-pyrrole-1-hexanoic Acid, 2,5-dihydro-2,5-dioxo-, (2e)-2-(1-((2s,4s)-4-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide
29. 1h-pyrrole-1-hexanoic Acid, 2,5-dihydro-2,5-dioxo-, (2e)-2-[1-[(2s,4s)-4-[(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
30. N'-((1e)-1-((2s,4s)-4-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxohexopyranosyl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl(-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)hexanohydrazide
31. N'-((e)-1-((2s,4s)-4-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)hexanehydrazide
Molecular Weight | 750.7 g/mol |
---|---|
Molecular Formula | C37H42N4O13 |
XLogP3 | 1.3 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 12 |
Exact Mass | 750.27483741 g/mol |
Monoisotopic Mass | 750.27483741 g/mol |
Topological Polar Surface Area | 268 Ų |
Heavy Atom Count | 54 |
Formal Charge | 0 |
Complexity | 1510 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in solid tumors.
INNO-206 is the (6-Maleimidocaproyl) hydrazone of doxorubicin. INNO-206 is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker. In preclinical models, INNO-206 was superior to doxorubicin with regard to antitumor efficacy and toxicity.
ABOUT THIS PAGE
A Aldoxorubicin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aldoxorubicin, including repackagers and relabelers. The FDA regulates Aldoxorubicin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aldoxorubicin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aldoxorubicin supplier is an individual or a company that provides Aldoxorubicin active pharmaceutical ingredient (API) or Aldoxorubicin finished formulations upon request. The Aldoxorubicin suppliers may include Aldoxorubicin API manufacturers, exporters, distributors and traders.
Aldoxorubicin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aldoxorubicin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aldoxorubicin GMP manufacturer or Aldoxorubicin GMP API supplier for your needs.
A Aldoxorubicin CoA (Certificate of Analysis) is a formal document that attests to Aldoxorubicin's compliance with Aldoxorubicin specifications and serves as a tool for batch-level quality control.
Aldoxorubicin CoA mostly includes findings from lab analyses of a specific batch. For each Aldoxorubicin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aldoxorubicin may be tested according to a variety of international standards, such as European Pharmacopoeia (Aldoxorubicin EP), Aldoxorubicin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aldoxorubicin USP).
LOOKING FOR A SUPPLIER?